Your browser doesn't support javascript.
loading
The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer: a study of the SONABRE registry.
Lammers, Senna W M; Thurisch, Hannah; Vriens, Ingeborg J H; Meegdes, Marissa; Engelen, Sanne M E; Erdkamp, Frans L G; Dercksen, M Wouter; Vriens, Birgit E P J; Aaldering, Kirsten N A; Pepels, Manon J A E; van de Winkel, Linda M H; Peters, Natascha A J B; Tol, Jolien; Heijns, Joan B; van de Wouw, Agnes J; Teeuwen, Nathalie J A; Geurts, Sandra M E; Tjan-Heijnen, Vivianne C G.
Afiliación
  • Lammers SWM; Department of Medical Oncology, Maastricht University Medical Centre, GROW, Maastricht University, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands.
  • Thurisch H; Department of Medical Oncology, Maastricht University Medical Centre, GROW, Maastricht University, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands.
  • Vriens IJH; Department of Medical Oncology, Maastricht University Medical Centre, GROW, Maastricht University, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands.
  • Meegdes M; Department of Medical Oncology, Maastricht University Medical Centre, GROW, Maastricht University, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands.
  • Engelen SME; Department of Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Erdkamp FLG; Department of Internal Medicine, Zuyderland Medical Centre, Sittard-Geleen, The Netherlands.
  • Dercksen MW; Department of Medical Oncology, Máxima Medical Centre, Eindhoven, The Netherlands.
  • Vriens BEPJ; Department of Internal Medicine, Catharina Hospital, Eindhoven, The Netherlands.
  • Aaldering KNA; Department of Internal Medicine, Laurentius Hospital, Roermond, The Netherlands.
  • Pepels MJAE; Department of Internal Medicine, Elkerliek Hospital, Helmond, The Netherlands.
  • van de Winkel LMH; Department of Internal Medicine, St. Anna Hospital, Geldrop, The Netherlands.
  • Peters NAJB; Department of Internal Medicine, St. Jans Gasthuis, Weert, The Netherlands.
  • Tol J; Department of Internal Medicine, Jeroen Bosch Hospital, Den Bosch, The Netherlands.
  • Heijns JB; Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands.
  • van de Wouw AJ; Department of Internal Medicine, Viecuri Medical Centre, Venlo, The Netherlands.
  • Teeuwen NJA; Department of Medical Oncology, Maastricht University Medical Centre, GROW, Maastricht University, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands.
  • Geurts SME; Department of Medical Oncology, Maastricht University Medical Centre, GROW, Maastricht University, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands.
  • Tjan-Heijnen VCG; Department of Medical Oncology, Maastricht University Medical Centre, GROW, Maastricht University, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands. vcg.tjan.heijnen@mumc.nl.
Breast Cancer Res Treat ; 203(2): 339-349, 2024 Jan.
Article en En | MEDLINE | ID: mdl-37878148
PURPOSE: This study determines the prognostic impact of body mass index (BMI) in patients with hormone receptor-positive/human epidermal growth factor receptor-2-negative (HR+/HER2-) advanced (i.e., metastatic) breast cancer (ABC). METHODS: All patients with HR+/HER2- ABC who received endocrine therapy +-a cyclin-dependent kinase 4/6 inhibitor as first-given systemic therapy in 2007-2020 in the Netherlands were identified from the Southeast Netherlands Advanced Breast Cancer (SONABRE) registry (NCT03577197). Patients were categorised as underweight (BMI: < 18.5 kg/m2), normal weight (18.5-24.9 kg/m2), overweight (25.0-29.9 kg/m2), or obese (≥ 30.0 kg/m2). Overall survival (OS) and progression-free survival (PFS) were compared between BMI classes using multivariable Cox regression analyses. RESULTS: This study included 1456 patients, of whom 35 (2%) were underweight, 580 (40%) normal weight, 479 (33%) overweight, and 362 (25%) obese. No differences in OS were observed between normal weight patients and respectively overweight (HR 0.99; 95% CI 0.85-1.16; p = 0.93) and obese patients (HR 1.04; 95% CI 0.88-1.24; p = 0.62). However, the OS of underweight patients (HR 1.45; 95% CI 0.97-2.15; p = 0.07) tended to be worse than the OS of normal weight patients. When compared with normal weight patients, the PFS was similar in underweight (HR 1.05; 95% CI 0.73-1.51; p = 0.81), overweight (HR 0.90; 95% CI 0.79-1.03; p = 0.14), and obese patients (HR 0.88; 95% CI 0.76-1.02; p = 0.10). CONCLUSION: In this study among 1456 patients with HR+/HER2- ABC, overweight and obesity were prevalent, whereas underweight was uncommon. When compared with normal weight, overweight and obesity were not associated with either OS or PFS. However, underweight seemed to be an adverse prognostic factor for OS.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Límite: Female / Humans Idioma: En Revista: Breast Cancer Res Treat Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Límite: Female / Humans Idioma: En Revista: Breast Cancer Res Treat Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Países Bajos